No Data
No Data
No Data
No Data
No Data
Sunshine Novo (688621.SH) announced first-quarter results, net profit of 72.7538 million yuan, an increase of 51.77% over the previous year
According to Zhitong Finance App News, Sunshine Nuohe (688621.SH) released its report for the first quarter of 2024. The company's revenue was 252 million yuan, up 8.53% year on year; net profit attributable to shareholders of listed companies was 72.7538 million yuan, up 51.77% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 666.201 million yuan, an increase of 41.68% year on year; basic earnings per share were 0.65 yuan/share.
Zhitong FinanceApr 25 11:02 ET
China Merchants Securities: Demand for outsourcing generic drug development services increases, and the performance of listed companies related to generic CRO maintains a relatively rapid growth rate
From a long-term development perspective, imitation CRO related companies are expected to fully benefit from advanced market demand, business model innovation, and customer base expansion, and achieve continuous growth in performance. First-tier enterprises are expected to increase their market share in industrial upgrading competition.
Zhitong FinanceApr 16 02:02 ET
Sunshine Novo (688621.SH): Ruiying Management, Ruiying Investment, Guangzhou Zhengda, Haida Mingde, and Huipu Zofang reduced their total holdings by 1.1855%
Glonghui, March 1, 丨 Sunshine Novo (688621.SH) announced that the company received the “Notice Letter on Implementation Progress and Equity Changes in the Shares Reduction Plan of Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd.” issued by shareholders Ruiying Management, Ruiying Investment, Guangzhou Zhengda, Haida Mingde, and HPP ZF through centralized bidding transactions. The number of shares reduced by 1.1855% of the company's total share capital was 1.1855% of the company's total share capital. The current holdings reduction plan has expired.
Gelonghui FinanceMar 1 05:03 ET
Sunshine Novo (688621.SH)'s net profit of 194 million yuan in 2023 increased 24.43% year-on-year
Sunshine Novo (688621.SH) disclosed its 2023 annual performance report. During the reporting period, the company achieved operating income...
Zhitong FinanceFeb 26 04:49 ET
Sunshine Novo (688621.SH): The company currently has 36,300 square meters of R&D laboratory, with more than 80% of the laboratory area already in use
Gelonghui, January 2丨Sunshine Nuohe (688621.SH) received a survey from specific subjects and said that the company currently has 36,300 square meters of R&D laboratory, and more than 80% of the laboratory area has been put into use. The company has established synthesis laboratories, testing laboratories, microbiology laboratories, etc. at its headquarters in Changping, Beijing, including laboratories for the development of various dosage forms; Beijing Fengtai has built a clinical phase I-III trial center and PK/PD analysis laboratory for small chemical molecules and biomacromolecules; Beijing Daxing and Yizhuang International Biomedical Park have established separate pediatric drug platforms and TDS drug laboratories for childhood diseases
Gelonghui FinanceJan 2 03:35 ET
Sunshine Nuohe (688621.SH): More than 40 new self-developed projects were set up in the first half of the year, and the total number has exceeded 290
Gelonghui, December 6 | Sunshine Nuohe (688621.SH) recently stated during a survey by institutional investors that in the first half of 2023, the company set up more than 40 new self-research projects, totaling more than 290; in the company's participation in R&D and independent R&D projects, a total of 3 new drug projects have passed NMPA approval to enter clinical trials, 47 drug applications have been accepted for marketing registration, and 7 consistency evaluations have been accepted; with mature R&D technology platforms and project reporting capabilities, the company has signed joint development project agreements with many enterprises, including 6 types of equity, have been approved, including approval Amopressin injection, pimex
Gelonghui FinanceDec 6, 2023 02:48 ET
No Data
No Data